CN102970971A - 美沙拉嗪栓剂 - Google Patents

美沙拉嗪栓剂 Download PDF

Info

Publication number
CN102970971A
CN102970971A CN2010800632711A CN201080063271A CN102970971A CN 102970971 A CN102970971 A CN 102970971A CN 2010800632711 A CN2010800632711 A CN 2010800632711A CN 201080063271 A CN201080063271 A CN 201080063271A CN 102970971 A CN102970971 A CN 102970971A
Authority
CN
China
Prior art keywords
suppository
mesalazine
mesalamine
measured
scope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800632711A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·鲍威尔
伊夫·迪穆兰
卡尔·高蒂尔
乌格斯·莫罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma Canada ULC
Original Assignee
Axcan Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102970971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axcan Pharma Inc filed Critical Axcan Pharma Inc
Publication of CN102970971A publication Critical patent/CN102970971A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800632711A 2009-12-16 2010-12-16 美沙拉嗪栓剂 Pending CN102970971A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/639,645 2009-12-16
US12/639,645 US8436051B2 (en) 2007-06-08 2009-12-16 Mesalamine suppository
PCT/US2010/060849 WO2011084638A2 (en) 2009-12-16 2010-12-16 Mesalamine suppository

Publications (1)

Publication Number Publication Date
CN102970971A true CN102970971A (zh) 2013-03-13

Family

ID=43901620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800632711A Pending CN102970971A (zh) 2009-12-16 2010-12-16 美沙拉嗪栓剂

Country Status (14)

Country Link
US (2) US8436051B2 (cg-RX-API-DMAC10.html)
EP (1) EP2512443A2 (cg-RX-API-DMAC10.html)
JP (1) JP2013514979A (cg-RX-API-DMAC10.html)
KR (1) KR20120104604A (cg-RX-API-DMAC10.html)
CN (1) CN102970971A (cg-RX-API-DMAC10.html)
AU (1) AU2010339837A1 (cg-RX-API-DMAC10.html)
CA (2) CA2690450A1 (cg-RX-API-DMAC10.html)
CL (1) CL2012001636A1 (cg-RX-API-DMAC10.html)
IL (1) IL220397A0 (cg-RX-API-DMAC10.html)
MX (1) MX2012006902A (cg-RX-API-DMAC10.html)
RU (1) RU2012125186A (cg-RX-API-DMAC10.html)
SG (1) SG181169A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011084638A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201204422B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622974A (zh) * 2013-12-05 2014-03-12 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
EP2166128B1 (de) 2008-09-19 2011-11-09 Oerlikon Trading AG, Trübbach Verfahren zum Herstellen von Metalloxidschichten durch Funkenverdampfung
WO2012032185A1 (de) * 2010-09-10 2012-03-15 Pharmazell Gmbh Verfahren zur herstellung kristalliner 5-aminosalicylsäure
WO2013059768A1 (en) * 2011-10-20 2013-04-25 Aptalis Pharma U.S., Inc. Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract
US20160175271A1 (en) * 2014-12-19 2016-06-23 Gavis Pharmaceuticals Rectal suppository for ulcerative colitis
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
BR112022008118A2 (pt) * 2019-10-31 2022-07-19 Scherer Technologies Llc R P Cápsula de supositório
KR20250042058A (ko) 2023-09-19 2025-03-26 한양대학교 산학협력단 염증성 장 질환 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090022793A1 (en) * 2007-06-08 2009-01-22 Axcan Pharma Inc. Mesalamine suppository
US20090264386A1 (en) * 2007-06-08 2009-10-22 Axcan Pharma Inc. Mesalamine suppository

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689514A (en) * 1969-05-21 1972-09-05 Schlueter Edelfett Suppository vehicle and process of making same
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4374932A (en) * 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
JPH0816051B2 (ja) * 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US5629012A (en) * 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
GB9201857D0 (en) * 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US5389375A (en) * 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
CA2231176C (en) * 1995-09-07 2008-04-01 Taisho Pharmaceutical Co., Ltd. Long active composition for rectal administration
JPH09323934A (ja) * 1996-05-31 1997-12-16 Kanebo Ltd 保存安定性の改善された坐剤
CA2285923C (en) 1997-04-01 2013-03-12 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US7341741B1 (en) * 1997-09-26 2008-03-11 Jean-Pierre Sachetto Pharmaceutical composition for the treatment of inflammatory bowel disease
CN1280489A (zh) * 1997-10-08 2001-01-17 大正制药株式会社 栓剂组合物
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6610674B1 (en) * 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020037855A1 (en) * 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
ATE311358T1 (de) * 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
EP1542708A4 (en) * 2002-08-23 2006-04-19 Zymogenetics Inc METHOD FOR THE TREATMENT OF REMOVAL OF NON-DISEASE DISEASE
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
AU2004314731B2 (en) * 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US7326809B2 (en) * 2004-05-27 2008-02-05 Antibe Therapeutics Inc. Salts of 4- or 5-aminosalicylic acid
CZ296169B6 (cs) * 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007103373A2 (en) * 2006-03-07 2007-09-13 Combinatorx, Incorporated Compositions and methods for the treatment of immunoinflammatory disorders
US20070240236A1 (en) * 2006-04-05 2007-10-11 Oklahoma Medical Research Foundation O-glycans in the treatment of inflammatory bowel disease and cancers
NZ572049A (en) * 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2008031013A1 (en) * 2006-09-08 2008-03-13 Gene Logic Inc. Method for treating inflammatory diseases of the digestive tract
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090022793A1 (en) * 2007-06-08 2009-01-22 Axcan Pharma Inc. Mesalamine suppository
US20090264386A1 (en) * 2007-06-08 2009-10-22 Axcan Pharma Inc. Mesalamine suppository

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622974A (zh) * 2013-12-05 2014-03-12 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法

Also Published As

Publication number Publication date
RU2012125186A (ru) 2014-01-27
ZA201204422B (en) 2013-08-28
IL220397A0 (en) 2012-08-30
US8436051B2 (en) 2013-05-07
US9884018B2 (en) 2018-02-06
WO2011084638A2 (en) 2011-07-14
EP2512443A2 (en) 2012-10-24
CA2690450A1 (en) 2011-06-16
US20100105639A1 (en) 2010-04-29
MX2012006902A (es) 2012-10-05
AU2010339837A1 (en) 2012-06-28
KR20120104604A (ko) 2012-09-21
CL2012001636A1 (es) 2012-10-12
US20130231310A1 (en) 2013-09-05
SG181169A1 (en) 2012-07-30
WO2011084638A3 (en) 2012-04-05
JP2013514979A (ja) 2013-05-02
CA2784772A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
US9884018B2 (en) Mesalamine suppository
ES2731367T3 (es) Formulaciones de cannabinoides sólidas orales, métodos para producir y utilizar las mismas
CN108366962A (zh) 治疗物质的组合物、其方法和用途
CN105073127A (zh) 用于治疗肠纤维化的口服类固醇制剂
JPWO2016117621A1 (ja) ω３脂肪酸の自己乳化組成物
CN103957888A (zh) 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
JP2025066774A (ja) 炎症性腸疾患を治療する際の使用のための乳汁由来の細胞外小胞
US8217083B2 (en) Mesalamine suppository
JP6262843B2 (ja) 潰瘍性大腸炎の治療のためのホスファチジルコリンを含む医薬製剤
US7541384B2 (en) Mesalamine suppository
CN108888670A (zh) 一种治疗溃疡性结肠炎的结肠靶向胶囊剂及其制备工艺
US11376217B2 (en) Hydrocortisone acetate suppository formulation for treatment of disease
JP2017509630A (ja) プロゲステロン製剤
JP2023113819A (ja) 脂質組み合わせ
WO2013035113A1 (en) Coated suppositories
CN113813223A (zh) 一种微型栓剂及其组合物和制备方法
Iwobi Suppository Solid Provision Technology
MD3319586T2 (ro) Formulări farmaceutice pentru tratamentul afecțiunilor inflamatorii ale rectului
CN101001622A (zh) 对于咀嚼稳定的胶囊
CN105434333B (zh) 美索舒利栓剂及其制备方法和用途
WO2012006967A1 (zh) 在栓剂组合物中的聚氧化乙烯及基质型表面活性剂
LING Evaluation and characterisation of bioadhesive suppositories formulated using commercial hydrogenated palm kernel stearin
BR112019021391A2 (pt) cápsulas de pululano
TW201545774A (zh) 用於治療尿路結石之醫藥品及其製備方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130313